Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Trump signs bill allowing whole milk to return to school lunches - 2NASA's Perseverance Mars rover could break the record for miles driven on another planet
- 3Vote in favor of your Number one method for commending a birthday
- 4Gilead's new HIV prevention shot added to CVS's drug coverage lists, CEO says
- 5‘Dying of thirst’: Inside Gaza’s al-Mawasi water crisis
- Vote in favor of your #1 Kind of Cap
- UAE used military bases in Red Sea region to aid Israel's war against Hamas, leaks reveal
- Gulf of Mexico oil spill spread hundreds of miles, killed wildlife and polluted Mexican reserves
- My Enterprising Excursion: Building a Startup
- Physicists and philosophers have long struggled to understand the nature of time: Here's why
- First Phosphate advances battery-grade phosphate project as analysts highlight strategic Federal support
- 'Euphoria' releases Season 3 photos with Zendaya, Sydney Sweeney, Jacob Elordi and others: See them
- Beating Scholastic Difficulties: Understudy Examples of overcoming adversity
- Eleven Creations And Developments That Steered History
